Peptide Purity
Peptide purity reported as an HPLC area percent is the main peak's share of the included peak area.
Paste this code into your page. It shows the COA field explainer with one plain credit link.
Learn
The short version
That makes it a ratio of peak areas, not a weight. A purity of 98 percent says the main peak is 98 percent of the included peak area. The other 2 percent is spread over the other included peaks. Those can be close relatives of the peptide, such as chains with one amino acid missing. Peaks from the solvent, the reagents, the mobile phase or the sample matrix are not counted, and neither are peaks at or below a set cutoff.
What the percent leaves out matters just as much. Water, salt and anything the detector cannot see are not in it. To read the purity line on your own COA, use the COA peptide checker.
Sources: US Pharmacopeia chapter 621, Chromatography, 2022 text, for purity as a ratio of peak areas and the peaks not counted; European Medicines Agency guideline on synthetic peptides, 2025, for chains with an amino acid missing.
How peptide purity is worked out
- The lab dissolves a small amount of the sample.
- It runs the sample through an HPLC column. The parts come out at different times.
- A UV detector draws a line as they come out. Each part makes a peak.
- Software measures the area under each peak.
- Purity = main peak area ÷ total area of the included peaks × 100.
The US Pharmacopeia calls step 5 the normalization procedure. It leaves some peaks out of the total: those from the solvent, the reagents, the mobile phase or the sample matrix, and those at or below a set cutoff.
Here is a worked example with made up numbers. The main peak has an area of 980 units. Three small peaks have 12, 5 and 3 units. The total is 1,000. Purity is 980 ÷ 1,000 × 100 = 98 percent.
The HPLC peptide testing page explains the column, the detector and the wavelength.
Sources: US Pharmacopeia chapter 621, Chromatography, 2022 text, for the normalization procedure; the worked example is calculated here from made up peak areas.
What the purity percent does not show
- How much of the powder is peptide. That is peptide content, or assay. It can be lower than purity, because a powder can hold water and salt.
- Which molecule the main peak is. HPLC sees a peak, not a name. EU guidance recommends at least two different methods for identity, such as mass and amino acid analysis.
- Impurities that hide. Two molecules can come out at the same time and look like one peak. EU guidance for peptide medicines warns about these co-eluting impurities.
- Endotoxin or microbes. Those need their own tests. See endotoxin test.
Sources: European Medicines Agency guideline on synthetic peptides, 2025, section 4.4, on identity methods and impurities that come out together.
Purity vs peptide content
These two numbers answer different questions.
| Purity (HPLC area percent) | Peptide content (assay) | |
|---|---|---|
| Question | What share of the included peak area is the main peak? | What share of the powder's weight is the peptide? |
| What lowers it | Related peptides and other UV-visible impurities | Water, salt (counterion), and impurities |
| How it is measured | HPLC with a UV detector | HPLC against a reference standard, amino acid analysis, nitrogen analysis or qNMR |
Salt can weigh a lot. Peptides can be made as salts. EU guidance says acetate is the usual counterion, and names trifluoroacetate (TFA) as another. In a 2025 study, TFA made up as much as 35 percent of the weight of some peptide salts. So a powder can show high purity and still be much less than 100 percent peptide by weight. EU guidance asks makers to give assay limits on a salt free, water free basis.
Sources: US Pharmacopeia chapter 621, Chromatography, 2022 text, for purity as a share of the included peak area; European Medicines Agency guideline on synthetic peptides, 2025, for the assay methods and the salt free basis; the 2025 paper on TFA as a counterion, in the journal Pharmaceuticals, for the 35 percent figure.
How regulators set purity limits
For peptide medicines in the EU, the European Pharmacopoeia sets thresholds for impurities that come from the peptide itself. EU guidance quotes them:
- report each one above 0.1 percent,
- identify each one above 0.5 percent,
- back it with safety study data (qualify it) above 1.0 percent.
These rules apply to medicines made under EU rules. They are given here to show how much detail a full purity test can carry. They are not a scale for grading a research product.
Sources: European Medicines Agency guideline on synthetic peptides, 2025, section 4.4.1, which quotes the European Pharmacopoeia thresholds.
Reading the purity line on a COA
Look for these four things next to the percent.
- The method. HPLC or UPLC, and whether the column and detector are named.
- The wavelength. Usually 210 to 220 nm for peptides.
- The limit. The minimum the lab or maker set, so you know what the result was held to.
- The chromatogram. The trace with the peaks. A report may attach it.
A lab's own report can confirm all of this. See COA verification.
Sources: Mant and others, 2007, for the 210 to 220 nm range; FDA Q7 guidance, 2016, paragraph 11.42, for the limit next to a result.
Questions
What does peptide purity mean?
When a COA reports peptide purity as an HPLC area percent, it is the main peak's share of the included peak area. A purity of 98 percent means the other included peaks add up to 2 percent of that area. Solvent, reagent, mobile phase and matrix peaks, and peaks at or below a set cutoff, are left out. It is not the share of the powder that is peptide.
What is a peptide purity test?
A peptide purity test is a lab run, such as HPLC with a UV detector, that splits a sample into peaks. The lab measures each peak's area and reports the main peak as a percent of the included peak area. A full report also gives the method, wavelength and limit.
How do labs test peptide purity?
One method is reversed phase HPLC, which one review calls the most widely used HPLC mode for peptides. The sample runs through a column, parts come out at different times, and a UV detector near 210 to 220 nm records peaks. Purity is the main peak area divided by the included peak area, times 100.
What is HPLC purity?
HPLC purity is the area of the main peak divided by the area of the included peaks in an HPLC run, times 100. Peaks from the solvent, reagents, mobile phase or sample matrix are left out, and so are peaks at or below a set cutoff. It depends on what the detector can see at the wavelength used. It does not include water or salt.
What is the difference between purity and assay in HPLC?
Purity compares the main peak with the other included peaks in the same run. Assay measures how much of the target is in the sample by weight, for example against a reference standard. Water and salt lower assay but do not show in purity.
Sources: US Pharmacopeia chapter 621, Chromatography, 2022 text, for the main peak area over the included peak area and the peaks left out; Mant and others, 2007, the review of reversed phase HPLC of peptides and the UV range; European Medicines Agency guideline on synthetic peptides, 2025, for assay against a reference standard.
Sources
6 sources with read dates
- HPLC Analysis and Purification of Peptides, Mant CT and others, Methods Mol Biol 2007, PMID 18604941; full text read on PubMed Central (PMC7119934), read 2026-10-06
- General Chapter 621, Chromatography, harmonized text official 1 December 2022, United States Pharmacopeia; the copy of USP's own file kept by the Internet Archive on 7 December 2023, normalization procedure, read 2026-10-08
- Guideline on the Development and Manufacture of Synthetic Peptides, European Medicines Agency, EMA/CHMP/CVMP/QWP/367182/2025, sections 4.3.2 and 4.4, read 2026-10-06
- Towards a Consensus for the Analysis and Exchange of TFA as a Counterion in Synthetic Peptides, Pharmaceuticals (Basel) 2025, PMID 40872554; full text read on PubMed Central (PMC12389442), read 2026-10-06
- Q2(R2) Validation of Analytical Procedures, FDA and ICH, March 2024, section 3.1, read 2026-10-06
- Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, FDA, September 2016, paragraph 11.42, read 2026-10-06